MRK Merck & Company Inc
Company Analysis
Latest News
Merck faces Keytruda patent cliff, ending the era of blockbuster cancer drugs
Merck’s Keytruda faces a patent cliff in 2028. This milestone signals the end of the single, dominant blockbuster era in oncology. The market is shifting...
🟢 Merck & Co Inc is trading 5.1% up today on pipeline optimism and broader defensive market rotation
Merck & Company Inc is trading 5.1% up at $120.52, benefiting from positive pipeline developments and a broader market shift into defensive and healthcare...
🟢 Merck & Company Inc is trading 3.4% up today on defensive rotation and positive analyst sentiment
Merck & Company Inc is trading 3.4% up at $118.57 as the stock benefits from a rotation into defensive, value-oriented names within the Dow. • The stock is...
🟢 Merck & Company Inc is trading 4.16% up
MRK is trading at $119.47, up 4.16%.
🔴 Merck & Company Inc is trading 3.18% down today after mixed ASCO oncology data and profit-taking
Merck & Company Inc is trading at $114.95 (-3.18%) following mixed oncology news flow from the ASCO conference and a broader reset in investor expectations. •...
Merck Secures $4 Billion Norges Bank Stake Following FDA Cancer Drug Win
Norges Bank, Norway’s central bank, purchased approximately 37.98 million shares of Merck. This stake is valued at roughly $4.0 billion. The investment gives...
Merck Secures FDA Breakthrough Status for Calderasib-Keytruda Lung Cancer Combo
Merck announced the FDA granted Breakthrough Therapy Designation to its investigational drug calderasib (MK-1084). The designation covers calderasib in...
CVC Bids $12.4B for Recordati, Merck Lung Cancer Trial Cuts Risk 65%
A consortium led by CVC Capital Partners and Groupe Bruxelles Lambert launched a €10.7 billion ($12.4 billion) cash bid for Italian drugmaker Recordati. The...
Merck's first quarter 2026 revenue grew 5% on KEYTRUDA strength, prompting a raise in full-year guidance.
Merck reported first quarter 2026 sales of $16.3 billion, a 5% increase year-over-year, driven by its Oncology and Animal Health divisions. The company posted...
Merck & Company Inc Q1 2026 Earnings Preview: What Analysts Expect on April 30, 2026
Wall Street expects Merck & Co. to report first-quarter 2026 revenue of approximately $15.90 billion and a consensus EPS loss of $1.51, while the stock...
Big Pharma buys smaller biotechs, boosting sector stocks to fill pipelines
Large pharmaceutical companies are prioritizing strategic bolt-on acquisitions over megadeals. These transactions typically range in the low-single-digit...